Escalating semaglutide (Ozempic) from 1 mg to 2 mg was associated with a 6% lower risk of major adverse cardiovascular events (MACE) vs switching to tirzepatide (Mounjaro) in adults with type 2 diabetes, according to real-world COMPETE SWITCH CV data from Novo Nordisk presented at EASD 2026.1
The analysis addresses a frequent decision point in practice: whether to intensify glucagon-like peptide-1 receptor agonist (GLP-1 RA) therapy with a higher semaglutide dose or move to tirzepatide, a dual glucose-dependent insulinotropic polypeptide (GIP)/GLP-1 RA. An earlier COMPETE SWITCH analysis, presented at the American Diabetes Association Scientific Sessions in June 2026, examined HbA1c and weight outcomes in the same population.2 The cardiovascular findings arrive 1 month after the FDA approved tirzepatide to reduce cardiovascular risk in adults with type 2 diabetes.4
"Treatment intensification is a common challenge we face in clinical practice, particularly for adults with type 2 diabetes who have not yet met their treatment goals but are otherwise tolerating their current regimen well," said Kathryn S. Tierney, MSN, APRN, FNP-BC, FAANP, Middlesex Health MultiSpecialty Group, Middletown, Connecticut. "The analysis reinforces the importance of considering cardiovascular outcomes, alongside glycemic management, when making treatment decisions."
Frequently Asked Questions
What did the COMPETE SWITCH CV analysis show?
In a retrospective US claims analysis, adults with type 2 diabetes who escalated semaglutide from 1 mg to 2 mg had a 6% lower adjusted MACE risk than those who switched to tirzepatide, according to Novo Nordisk (adjusted HR, 1.06; 95% CI, 1.04–1.08).
Does COMPETE SWITCH CV establish a causal cardiovascular advantage for semaglutide 2 mg?
No. As a retrospective real-world analysis, it demonstrates association rather than causation, may reflect residual unmeasured confounding, and did not assess safety outcomes.
How many patients were included in the MACE analysis?
The cardiovascular analysis included 185,705 adults who escalated to semaglutide 2 mg and 23,104 who switched to tirzepatide, drawn from 636,525 adults initially receiving semaglutide 1 mg.
COMPETE SWITCH CV design and semaglutide 2 mg MACE results
COMPETE SWITCH is a retrospective cohort study drawing on Komodo Health's Healthcare Map, a US claims database with linked laboratory results spanning January 2018 to September 2025.1 Investigators identified 636,525 adults with type 2 diabetes receiving once-weekly semaglutide 1 mg and compared outcomes after escalation to semaglutide 2 mg vs switching to tirzepatide up to 15 mg.1 The cardiovascular component used an intention-to-treat approach, following 185,705 adults who escalated and 23,104 who switched from the point of the treatment change.1
The composite MACE outcome comprised all-cause death, myocardial infarction, and stroke.1 According to Novo Nordisk, escalation to semaglutide 2 mg was associated with a 6% lower MACE risk compared with switching to tirzepatide (adjusted HR, 1.06; 95% CI, 1.04–1.08; P = .005).1 A subset of patients with more than 1 baseline HbA1c and/or weight measurement showed consistent results (adjusted HR, 1.07; 95% CI, 1.01–1.13; P < .035).1
Treatment intensification patterns and limitations of the real-world analysis
Within 365 days of the first semaglutide 1 mg fill, 67.2% of patients remained on the 1 mg dose, 29.2% escalated to 2 mg, and 3.6% switched to tirzepatide.1 By 720 days, the share on semaglutide 1 mg fell to 57.4%, while 36.9% had escalated and 5.7% had switched.1 Patients starting tirzepatide began at 2.5 mg or 5 mg, and approximately 31% reached a dose of 10 mg or higher during follow-up.1
Safety outcomes were not assessed in this analysis.1 Novo Nordisk noted real-world analyses may reflect residual unmeasured confounding and can demonstrate associations but cannot definitively establish causation.1 Reliance on retrospective claims data may also exclude patients with intermittent coverage or underserved populations, limiting generalizability.3
Semaglutide carries a Boxed Warning for possible thyroid tumors, including cancer, and should not be used in patients with a personal or family history of medullary thyroid carcinoma or multiple endocrine neoplasia syndrome type 2.1 The most common adverse events include nausea, vomiting, diarrhea, abdominal pain, and constipation.1
"These data may help inform healthcare professionals facing a critical challenge: whether to increase the dosage or switch to another therapy for an adult with type 2 diabetes who is already treated with semaglutide," said Michael Radin, MD, executive medical director, Novo Nordisk.
Novo Nordisk described the collective COMPETE SWITCH analyses as real-world insight into cardiometabolic outcomes associated with GLP-1 RA intensification strategies.1 The company also noted heterogeneity in individual treatment response may affect studies of dose titration and multiple sequential dosing.1
References
Novo Nordisk. Novo's Ozempic (semaglutide) 2 mg associated with lower risk of major adverse cardiovascular events (death, heart attack, and stroke) in adults with type 2 diabetes compared to switching to Mounjaro (tirzepatide), in real-world analysis. Published September 29, 2026. Accessed September 29, 2026. https://www.novonordisk.com/content/nncorp/global/en/news-and-media/news-and-ir-materials/news-details.html?id=917053
Fang G, Muhammad C, Swift C, et al. Cardiometabolic outcomes in adults with T2D treated with 1 mg semaglutide who titrate to 2 mg semaglutide vs switch to tirzepatide. Presented at: American Diabetes Association Scientific Sessions; June 5-8, 2026; New Orleans, LA.
Dang A. Real-world evidence: a primer. Pharmaceut Med. 2023;37:25-36. doi:10.1007/s40290-022-00456-6. https://doi.org/10.1007/s40290-022-00456-6
